Position statement - PERT shortage

Position statement - PERT shortage

Ongoing supply issues of pancreatic enzyme replacement therapy (PERT – under the product brands: Creon®, Nutrizym® and Pancrex®) mean some people are at risk of running out in the short-term or experiencing difficulties or delays in accessing their prescriptions.

New guidance has been developed by the BDA's Cystic Fibrosis and Gastroenterology Specialist Groups, alongside the Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland (NIGPS) to minimise the impact of these intermittent supply issues on symptoms.

Published: April 2024/ Updated: May 2024 (Version 2)